Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer
{{output}}
Multikinase inhibitors (MKIs) and highly selective tyrosine kinase inhibitors (HS-TKIs) positively impact the progression-free survival (PFS) of locally advanced and metastatic thyroid cancer cases. Moreover, disease-specific survival (DSS) and overall surviva... ...
